Skip to main content
. 2014 Apr 4;15(4):5838–5851. doi: 10.3390/ijms15045838

Figure 2.

Figure 2.

MET inhibitor PHA-665752 inhibits MET phosphorylation induced by cetuximab in Caco-2 cells. (A,B) Caco-2 cells were treated with cetuximab (10 μg/mL), PHA-665752 (0.4 μM) or both for 24 and 48 h in 2% FBS medium. Expression of MET, EGFR and phosphorylation levels, PARP and Caspase-3 were analyzed by Western blotting; (C) Caco-2 cells were treated with 10 μg/mL cetuximab or combination with 0.4 μM PHA-665752 for 48 h in 2% FBS medium, then followed by MTT assay. Results from three independent experiments are shown. Student’s t-test, * p < 0.05 for comparisons between cetuximab-treated and combined treatment; (D) Caco-2 cells were incubated with either 10 μg/mL cetuximab or 0.4 μM PHA-665752, or in combination treatment for 14 days, and the clones were counted.